Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Immunosuppressive Agents
  • Kidney Neoplasms
  • Sirolimus
  • Tumor Burden

abstract

  • This analysis identified baseline SLD as a predictive factor of OS, and the appearance of a new lesion or progression of a nontarget lesion at first assessment after baseline also affects OS in patients with mRCC treated with everolimus.

publication date

  • December 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2012.11.032

PubMed ID

  • 23219086

Additional Document Info

start page

  • 994

end page

  • 1002

volume

  • 64

number

  • 6